The interactions between human dendritic cells and microbes; possible clinical applications of dendritic cells

Inflammation Research

Volumn 53, Issue 9, 2004, Pages 413-423

  Kis, Z ^a,b   Pallinger, E ^c   Endresz, V ^b   Burian, K ^b   Jelinek, I ^c   Gonczol, E ^a   Valyi Nagy, I ^d  

^a NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d NATIONAL MEDICAL CENTER   (Hungary)

Author keywords

Human dendritic cells; Human pathogens; Infections

Indexed keywords

ALPHA INTERFERON; AZITHROMYCIN; CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC ASTHMA; ALLERGIC ENCEPHALOMYELITIS; ARTERY INTIMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLINDNESS; BURKITT LYMPHOMA; CANCER; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CELL SUBPOPULATION; CELLULAR IMMUNITY; CEREBROVASCULAR ACCIDENT; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COLORECTAL CANCER; CORONARY ARTERY DISEASE; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DENDRITIC CELL; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; HEART INFARCTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INFECTION; INFERTILITY; INSULIN DEPENDENT DIABETES MELLITUS; KAPOSI SARCOMA; KIDNEY CANCER; LARYNX CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; MICROENVIRONMENT; MICROORGANISM; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PAPILLOMA VIRUS; PENIS CARCINOMA; PNEUMONIA; PROSTATE CANCER; PROTEIN EXPRESSION; RETROVIRUS; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; VULVA CARCINOMA;

ARTERIOSCLEROSIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; HUMANS; INFECTION;

EID: 6044231811     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1274-0     Document Type: Review

References (86)

1. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106: 259-62.
2. Ardavin C. Origin, precursors and differentiation of mouse dendritic cells. Nature Rev Immunol 2003; 3: 582-90.
3. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Soc Acad Sci USA 1996; 93: 2588-92.
4. Makala LHC, Nagasawa H. Dendritic cells: a specialized complex system of antigen presenting cells. J Vet Med Sci 2002; 64: 181-93.
5. Szeberenyi JB, Pallinger E, Zsinko M, Pos Z, Rothe G, Orso E et al. Inhibition of effects of endogenously synthesized histamine disturbs in vitro human dendritic cell differentiation. Immunol Lett 2001; 76: 175-82.
6. Rescigno M. Dendritic cells and the complexity of microbial infection. Trends in Microbiol 2002; 10: 425-31.
7. Kozlow EJ, Wilson GL, Fox CH, Kehrl JH. Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes. Blood 1993; 81: 454-61.
8. Szeberenyi JB, Rothe G, Pallinger E, Orso E, Falus A, Schmitz G. Multi-color analysis of monocyte and dendritic cell precursor heterogeneity in whole blood. Immunobiol 2000; 2002: 51-8.
9. Reis e Sousa C. Dendritic cells as sensors of infection. Immunity 2001; 14: 495-8.
10. Fujimoto Y, Tu L, Miller AS, Bock C, Fujimoto M, Doyle C et al. CD83 expression influences CD4+ T cell development in the thymus. Cell 2002; 108: 755-67.
11. Lechmann M., Berchtold S, Hauber J, Steinkasserer A. CD83 on dendritic cells: more than just a marker for maturation. Trends in Immunol 2002; 23: 273-5.
12. Scholler N., Hayden-Ledbetter M, Dahlin A, Hellstrom I, Hellstrom KE, Ledbetter JA. Cutting edge: CD83 regulates the development of cellular immunity. J Immunol 2002; 168: 2599-602.
13. Dubois B, Bridon JM, Fayette J, Barthelemy C, Banchereau J, Caux C et al. Dendritic cells directly modulate B cell growth and differentiation J Leuc Biol 1999; 66: 224-30.
14. Palucka K, Banchereau J. How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr Opin in Immunol 2002; 14: 420-31.
15. Gogolak P, Rethi B, Hajas G, Rajnavolgyi E. Targeting dendritic cells for priming cellular immune responses. J Mol Recognit 2003; 16: 299-317.
16. Milone MC, Fitzgerald-Bocarsly P. The mannose receptor mediates induction of IFN-alfa in peripheral blood dendritic cells by enveloped RNA and DNA viruses. J Immunol 1998; 161: 2391-99.
17. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001; 166: 2961-9.
18. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opinion in Immunology 2002; 14: 432-6.
19. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002; 195: F9-F14.
20. Moretta I, Ferlazzo G, Mingari MC, Melioli G, Moretta A. Human natural cell function and their interaction with dendritic cells. Vaccine 2003; 21: Se/38-S2/42.
21. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003; 987: 15-25.
22. Accapezzato D, Francavilla V, Propato A, Paroli M, Barnaba V. Mechanisms inducing or controlling CD8+ T cell responses against self- or non-self-antigens. Ann N Y Acad Sci 2003; 987: 99-106.
23. Morel PA, Feili-Hariri M, Coates PT, Thomson AW. Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol 2003; 133: 1-10.
24. Waltner-Romen M, Falkensammer G, Rabl W, Wick G. A previously unrecognized site of local accumulation of mononuclear cells: the vascular-associated lymphoid tissue. J Histochem and Cytochem 1998; 46: 1347-50.
25. Millonig G, Malcom GT, Wick G. Early inflammatory-immunological lesions in juvenile atherosclerosis from the Pathobiological Determinants of Atherosclerosis in the Youth (PDAY)-study. Atherosclerosis 2002; 160: 441-8.
26. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-90.
27. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. Nature Reviews Immunol 2003; 3: 697-709.
28. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J et al. DC-SIGN, a dendritic cell-specific HIV-1 binding protein that enhances trans-infection of T cells. Cell 2000; 100: 587-97.
29. Colmenares M, Puig-Kroger A, Pello OM, Corbi AL, Rivas L. Dendritic cell (DC)-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN, CD209), a C-type surface lectin in human DCs, is a receptor for Leishmania amastigotes. J Biol Chem 2002; 227: 36766-9.
30. Tailleux L, Swartz O, Herrmann JL, Pivert E, Jackson M, Amara A et al. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med 2003; 197: 1-5.
31. Turville SG, Cameron PU, Handley A, Lin G, Pohlman S, Doms RW et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 2002; 3: 891-3.
32. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-9.
33. Rescigno M, Urbano M, Rimoldi M, Valzasina B, Rotta G, Granucci F et al. Toll-like receptor 4 is not required for the full maturation of dendritic cells or for the degradation of Gram-negative bacteria. Eur J Immunol 2002; 32: 2800-6.
34. Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294: 870-5.
35. de Jong EC, Vieira PL, Kalinski P, Schuitemaker JHN, Tanala Y, Wierenga EA et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals J Immunol 2002; 168: 1704-9.
36. Bender A, Albert M, Reddy A, Feldman M, Sauter B, Kaplan G et al. The distinctive features of influenza virus infection of dendritic cells. Immunobiol 1998; 198: 552-67.
37. Matyszak MK, Young JL, Gaston JSH. Uptake and processing of Chlamydia trachomatis by human dendritic cells. Eur J Immunol 2002; 32: 742-51.
38. Jiao X, Lo-Mann R, Guermonprez P, Fietta L, Deriaud E, Burgaud S et al. Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J Immunol 2002; 168: 1294-301.
39. Henderson RA, Watkins SC, Flynn JL. Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol 1997; 158: 635-43.
40. Klagge IM, Schneider-Schaulies S. Virus interactions with dendritic cells. J Gen Virol 1999; 80: 823-33.
41. Salio M, Cella M, Suter M, Lanzavecchia A. Inhibition of dendritic cells maturation by herpes simplex virus. Eur J Immunol 1999; 29: 3245-53.
42. Kruse M, Rosorius O, Kratzer F, Stelz G, Kuhnt C, Schuler G et al. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J Virol 74: 7127-36.
43. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA 1998; 95: 3937-42.
44. Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997; 276: 1851-4.
45. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1966; 64: 1614-20.
46. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000; 131: S4002-S410.
47. Burian K, Kis Z, Virok D, Endresz V, Prohaszka Z, Duba J et al. Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis. Circulation 2001; 103: 1503-8.
48. Burian K, Berencsi K, Endresz V, Gyulai Zs, Valyi-Nagy T, Valyi-Nagy I et al. Chlamydia pneumoniae exacerbates aortic inflammatory foci caused by murine cytomegalovirus infection in normocholesterolemic mice. Clin Diagn Lab Immunol 2001; 8: 1263-6.
49. Virok D, Kis Z, Karai L, Intzedy L, Burian K, Szabo A et al. Chlamydia pneumoniae in atherosclerotic middle cerebral artery. Stroke 2001; 32: 1973-6.
50. Virok D, Loboda A, Kari L, Nebozhyn M, Chang C, Nichols C et al. Infection of U937 monocytic cells with Chlamydia pneumoniae induces extensive changes in host cell gene expression. J Infect Dis 2003; 188: 1310-21.
51. Gieffers J, Füllgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-6.
52. Wong Y, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999; 34: 1435-9.
53. Kaul R, Uphoff J, Wideman J, Yadlapalli S, Wenman WM. Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease. Circulation 2000; 102: 2341-6.
54. Tondella ML, Talkington DF, Holloway BP, Dowell SF, Cowley K, Soriano-Gabarro M et al. Development and evaluation of real-time PCR-based fluorescence assay for detection of Chlamydia pneumoniae. J Clin Microbiol 2002; 40: 575-83.
55. Airenne S, Surcel HM, Alakarppa H, Laitinen K, Paavonen J, Saikku P et al. Chlamydia pneumoniae infection in human monocytes. Infect Immun 1999; 67: 1445-9.
56. Heinemann M, Susa M, Simnacher U, Marke R, Essig A. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Infect. Immun 1996; 64: 4872-5.
57. Haranaga S, Yagamuchi H, Friedman H, Izumi SI, Yamamoto Y. Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro. Infect Immun 2001; 69: 7753-9.
58. Rugonfalvi-Kis S, Endresz V, Madsen HO, Burian K, Duba J, Prohaszka Z et al. Association of Chlamydia pneumoniae with coronary artery disease and its progression is dependent on the modifying effect of mannose-binding lectin. Circulation 2002; 106: 1071-6.
59. Prebec S, Kirschning C, Dürr S, da Costa C, Donath B, Brand K, et al. Predominant role of a Toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. J Immunol 2001; 167: 3316-23.
60. Costa CP, Kirschning CJ, Busch D, Durr S, Tennen L, Heinzmann U et al. Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae. Eur J Immunol 2002; 32: 2460-70.
61. Berencsi K, Endresz V, Klurfeld D, Kari L, Kritchevsky D, Gonczol E. Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice. Cell Adhes Commun 1998; 5: 39-47.
62. Speir E, Modali R, Huang ES et al. Potential role of human cytomegalovirus and a p53 interaction in coronary restenosis. Science 1994; 265: 391-4.
63. th Edition, Lippincott Williams and Wilkins, Philadelphia 2001; 2675-705.
64. Sinclair JH, Baillie J, Bryant LA Taylor-Wiedemann JA, Sissons JG. Repression of human cytomegalovirus major immediate early gene expression in a monocytic cell line. J Gen Virol 1992; 73: 433-5.
65. Kondo k, Xu J, Mocarski ES. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors. Proc Natl Acad Sci USA 1996; 91: 11879-83.
66. Soderberg-Naucler C, Streblow DN, Fish KN, Allan-Yorke J, Smith PP, Nelson JA. Reactivation of latent human cytomegalovirus in CD14+ monocytes is differentiation dependent. J Virol 2001; 75: 7543-54.
67. Riegler S, Hebart H, Einsele H, Brossait P, Jahn G, Sinzger C. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol 2000; 81: 393-9.
68. Halary F, Amara A, Lortat-Jacob H, Messerle M, Delaunnay T, Housles C et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection Immunity 2002; 17: 653-64.
69. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Zs. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 2002; 99: 2913-21.
70. Arrode G, Boccaccio C, Abastado JP, Davrinche C: Cross-presentation of human cytomegalovirus pp65 (UL83) to CD8+ T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells. J Virol 2002; 76: 142-50.
71. Tabi Zs, Moutaftsi M, Borysiewicz LK. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class-I restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. J Immunol 2001; 166: 5695-703.
72. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live virions. Blood 2001; 97: 994-1000.
73. Fonteneau JF, Larsson M, Bhardwaj N. Interaction between dead cells and dendritic cells in the induction of antiviral CTL responses. Curr Opin in Immunol 2002; 14: 471-7.
74. Sallusto F. Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alfa. J Exp Med 1994; 179: 1109-18.
75. Hsieh SM, Pan SC, Hung CC, Tsai HC, Chen MY, Lee CN et al. Kinetics of antigen-induced phenotypic and functional maturation of human monocyte-derived dendritic cells. J Immunol 2001; 167: 6286-91.
76. Berger TG and Schultz ES. Dendritic cell-based immunotherapy. Curr Top Microbiol Immunol 2003; 276: 163-197.
77. Santini SM, Belardelli F. Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines. Stem Cells 2003; 21: 495-505.
78. Lu Hang, Zhong G. Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. Inf Immun 1999; 67: 1763-9.
79. Carlsson B, Cheng WS, Totterman TH, Essand M. Ex vivo stimulation of cytomegalovirus (CMV)-specific T cell using CMV pp65-modified dendritic cells as stimulators. Br J Haematol 2003; 121: 428-38.
80. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasowsky J et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104: 173-80.
81. Banchereau J, Palucka, K, Dhodapkar M, Burkeholder S, Taquet N, Rolland A et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Research 2001; 61: 6451-8.
82. Tanaka Y, Dowdy SF, Linehan DC, Eberlein TJ, Goedegebuure PS. Induction of antigen-specific CTL by recombinant HIV transactivating fusion protein-pulsed human monocyte-derived dendritic cells J Immunol 2003; 170: 1291-8.
83. Andre F, Schartz NEC, Movassagh M, Flament C, Pautier P, Morice P et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360: 295-305.
84. Shaw J, Grand V, Durling L, Crane D, Caldwell HD. Dendritic cells pulsed with a recombinant chlamydial major outer membrane protein antigen elicit a CD4+ type 2 rather than type 1 immune response that is not protective. Inf Immun 2002; 1097-105.
85. Engleman EG. Dendritic cell-based cancer immunotherapy. Seminars in Oncology 2003; 3: 23-9.
86. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann NY Acad Sci 2003; 987: 180-7.